聚乙二醇化蛋白質市場：按類型、按蛋白質、按應用、按最終用戶、按（地區）、規模、份額、展望、機會分析，2022-2030 年

聚乙二醇化是將活性聚乙二醇 (PEG) 添加到各種形式的治療性蛋白質中以對其進行化學修飾的過程。 這些經過化學修飾的治療性蛋白質被稱為聚乙二醇化蛋白質治療劑。 聚乙二醇化蛋白質療法用於多種疾病，包括癌症、血友病、類風濕性關節炎、強直性脊柱炎和克羅恩氏病。 聚乙二醇化是一個術語，描述了用聚乙二醇 (PEG)（一種無毒、非免疫原性聚合物）對生物分子進行共價修飾，以減少生物藥物的缺點。

聚乙二醇 (PEG) 因其“靜音”特性和生物相容性聲明而經常用於藥物輸送和納米技術。 人們普遍認為聚乙二醇化允許生物材料和顆粒遞送方法逃避免疫系統並延長循環壽命。 然而，蛋白質的聚乙二醇化是一個複雜的過程，可以使用多種方法進行，具體取決於蛋白質類型和應用。 惰性 PEG 串共價或非共價結合到感興趣的蛋白質。 另一個關鍵步驟是聚乙二醇化蛋白質的純化，這主要通過層析和靜電相互作用或分子大小來實現。

市場動態

市場主要參與者越來越多地採用無機策略，例如產品發布，預計將在預測期內推動市場增長。 例如，諾和諾德公司於2020年2月在美國推出的用於治療A型血友病患者的ESPEROCT，用於預防或減少出血事件、治療和控制出血、重組半衰期延長因子VIII替代療法、抗血友病因子（重組），聚乙二醇化-EXei，用於控制出血。

這項研究的主要特點

• 本報告對全球聚乙二醇化蛋白質市場進行了深入分析，提供了以 2021 年為基準年的預測期 (2022-2030) 的市場規模和復合年增長率 (CAGR%) 增長情況。
• 解釋了不同細分市場的潛在創收機會，並描述了針對該市場的有吸引力的投資建議矩陣。
• 它還提供了有關市場驅動因素、制約因素、機會、新產品發布和批准、市場趨勢、區域前景以及主要參與者採用的競爭戰略的重要見解。
• 它根據以下參數提供了全球聚乙二醇化蛋白質市場主要參與者的概況 - 公司亮點、產品組合、主要亮點、財務業績和戰略。
• 本研究涵蓋的主要公司包括 Biogen Inc、Pfizer Inc、UCB S.A.、Leadiant Biosciences, Inc.、Amgen Inc.、Thermo Fisher Scientific Inc.、Horizo□□n Therapeutics Plc.、Novo Nordisk A/S、F。 Hoffmann-La Roche AG、Bayer AG、BioMarin、RedHill Biopharma Ltd.
• 這份報告中的見解將使營銷人員和企業高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。我猜。
• 全球聚乙二醇化蛋白質市場報告面向該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
• 利益相關者將可以通過用於分析全球聚乙二醇化蛋白質市場的各種戰略矩陣輕鬆做出決策。

內容

第 1 章目的和先決條件

• 調查目的
• 先決條件
• 縮寫說明

第2章市場展望

• 報告內容
  • 市場定義和範圍
• 執行摘要
  • 市場概況：按類型分類
  • 市場概況：按蛋白質分類
  • 市場概況，按應用分類
  • 市場概況：按最終用戶分類
  • 市場概況：按地區
• 連貫機會圖 (COM)

第3章市場動態、規律及趨勢分析

• 市場動態
  • 司機
  • 約束因素
  • 市場機會
• 影響分析
• 市場趨勢
• 近期趨勢
• 收購和合作場景
• 技術概述
• 監管場景
• 管道分析
• 害蟲分析

第 4 章聚乙二醇化蛋白質的全球市場：冠狀病毒 (COVID-19) 大流行的影響

• 總體影響
• 對供需的影響
• COVID-19 對市場的影響

第 5 章聚乙二醇化蛋白質的全球市場：按類型，2017-2030

• 消耗品
• 服務

第 6 章聚乙二醇化蛋白質的全球市場：按蛋白質分類，2017-2030

• 集落刺激因子
• 干擾素
• 促紅細胞生成素
• 重組因子 VIII
• 其他

第 7 章聚乙二醇化蛋白質的全球市場：按應用分類，2017-2030

• 癌症
• 自身免疫性疾病
• 肝炎
• 多發性硬化症
• 血友病
• 消化系統疾病
• 其他

第 8 章聚乙二醇化蛋白質的全球市場：按最終用戶分類，2017-2030

• 製藥和生物技術公司
• 委託研究機構
• 學術研究所

第 9 章按地區劃分的聚乙二醇化蛋白質全球市場，2017-2030

• 北美
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地區
• 歐洲
• 英國
• 德國
• 意大利
• 法國
• 西班牙
• 俄羅斯
• 其他歐洲地區
• 亞太地區
• 中國
• 印度
• 日本
• 東盟
• 澳大利亞
• 韓國
• 其他亞太地區
• 中東
• 海灣合作委員會
• 以色列
• 其他中東地區
• 非洲
• 北非
• 中非
• 南非

第10章競爭格局

• Biogen Inc.
• Pfizer Inc.
• UCB S.A.
• Leadiant Biosciences, Inc.
• Amgen Inc.
• Thermo Fisher Scientific Inc.
• Horizon Therapeutics Plc.
• Novo Nordisk A/S
• F. Hoffmann-La Roche AG
• Bayer AG
• BioMarin
• RedHill Biopharma Ltd

第 11 章章節

• 調查方法
• 關於出版商

PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. PEGylated protein therapeutics are used in multiple conditions, such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and others. PEGylation is the term used to describe the covalent modification of biological molecules with the non-toxic, non-immunogenic polymer polyethylene glycol (PEG) in order to reduce the drawbacks of some biopharmaceuticals.

Due to its claimed "silent" qualities and biocompatibility, polyethylene glycol (PEG) is frequently used in medication delivery and nanotechnology. It is commonly accepted that PEGylation enables biomaterials and particle delivery methods to sidestep the immune system and extend circulation lifetimes. Nevertheless, PEGylation of proteins is a complicated procedure that can be completed using a variety of methods, depending on the type of the protein and the intended application. Inert PEG strings are covalently or non-covalently complexed with proteins of interest. Another crucial step is the purification of the PEGylated protein, which is mostly accomplished through chromatography and electrostatic interactions or molecular sizes.

Market Dynamics

Increasing adoption of inorganic strategies by key players in market such as product launch is expected to drive market growth over the forecast period. For instance, in February 2020, the Novo Nordisk launched ESPEROCT in the U.S. for the treatment of people with hemophilia A. It is a recombinant extended half-life factor VIII replacement therapy used to prevent or reduce the number of bleeding episodes, to treat and control bleeding, and to manage bleeding during surgery in people with hemophilia A. ESPEROCT is antihemophilic factor (recombinant), glycopegylated-exei.

Key features of the study:

• This report provides an in-depth analysis of the global PEGylated proteins market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global PEGylated proteins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Biogen Inc, Pfizer Inc, UCB S.A., Leadiant Biosciences, Inc., Amgen Inc., Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, BioMarin, RedHill Biopharma Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global PEGylated proteins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PEGylated proteins market

Detailed Segmentation:

• Global PEGylated Proteins Market, By Type:
  • Consumables
  • Services
• Global PEGylated Proteins Market, By Protein:
  • Colony-stimulating factor
  • Interferons
  • Erythropoietin
  • Recombinant factor VII
  • Other
• Global PEGylated Proteins Market, By Application:
  • Cancer
  • Autoimmune Disease
  • Hepatitis
  • Multiple Sclerosis
  • Hemophilia
  • Gastrointestinal Disorder
  • Others
• Global PEGylated Proteins Market, By End User:
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes
• Global PEGylated Proteins Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Biogen Inc, Pfizer Inc
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • Pfizer Inc
  • UCB S.A.
  • Leadiant Biosciences, Inc.,
  • Amgen Inc.
  • Thermo Fisher Scientific Inc.
  • Horizon Therapeutics Plc.
  • Novo Nordisk A/S
  • Hoffmann-La Roche AG
  • Bayer AG
  • BioMarin
  • RedHill Biopharma Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Protein
  • Market Snapshot, By Application
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pipeline Analysis
• PEST Analysis

4. Global PEGylated Proteins Market- Impact of Coronavirus (Covid-19) Pandemic

• Overall Impact
• Impact on Supply and Demand
• COVID-19 Impact on the market

5. Global PEGylated Proteins Market, By Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Consumables
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
• Services
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global PEGylated Proteins Market, By Protein, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Colony Stimulating Factor
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
  • Others
• Interferon
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Erythropoietin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Recombinant Factor VIII
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global PEGylated Proteins Market, By Application, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Autoimmune Disease
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Hepatitis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Multiple Sclerosis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Hemophilia
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Gastrointestinal Disorder
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global PEGylated Proteins Market, By End User, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Pharmaceutical and Biotechnology Companies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Contract Research Organizations
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Academic Research Institutes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global PEGylated Proteins Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Protein, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Biogen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• UCB S.A.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Leadiant Biosciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Thermo Fisher Scientific Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Horizon Therapeutics Plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• F. Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• BioMarin
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
• RedHill Biopharma Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

11. Section

• Research Methodology
• About Us